雾化吸入普通肝素治疗住院COVID-19患者:98例多中心病例系列
该回顾性、非对照、多中心单臂病例系列纳入98例实验室确诊的住院COVID-19患者,给予雾化吸入普通肝素(UFH)治疗。结果显示吸入UFH总体安全,APTT虽较基线有统计学显著升高但峰值仍在正常范围,氧合指标在开始吸入UFH后由恶化转为改善。
要点
- 吸入UFH后APTT仅轻度升高且峰值处于正常范围,未达临床相关水平。
- 严重不良事件为消化道溃疡出血需输血和大腿血肿,均发生于治疗性抗凝患者。
- 氧饱和度/FiO2比值与FiO2在开始吸入UFH前恶化、之后改善。
核心结论
- 住院COVID-19患者雾化吸入UFH总体安全,APTT升高虽具统计学意义但无临床相关性,需紧急开展随机评估。
研究设计与样本
- 回顾性、非对照、多中心单臂病例系列,纳入98例实验室确诊的住院COVID-19患者。
- 吸入雾化UFH剂量为5000 IU q8h、10 000 IU q4h或25 000 IU q6h,疗程6 ± 3(均值 ± 标准差)天。
主要发现
- 在稳定使用预防性或治疗性全身抗凝但未接受治疗性UFH输注的患者中,APTT由基线34 ± 10秒升至峰值38 ± 11秒(P < .0001)。
- 3例接受治疗性UFH输注者APTT由基线72 ± 20秒升至峰值84 ± 28秒(P = .17),差异无统计学意义。
- 2例发生严重不良事件:需输血的胃溃疡出血和大腿血肿,均在治疗性抗凝状态下。
- 16例发生轻微出血,其中13例处于治疗性抗凝状态。
- 氧饱和度/FiO2比值和FiO2在开始吸入UFH前恶化、之后改善(斜率变化,P < .001)。
临床怎么用
- 提示吸入UFH在住院COVID-19患者中安全性可接受,但APTT升高无临床相关性,暂不能据此推荐常规使用。
局限性
- 研究为回顾性、非对照、单臂设计,缺乏对照组,无法确立因果与疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To determine the safety and efficacy-potential of inhaled nebulised unfractionated heparin (UFH) in the treatment of hospitalised patients with COVID-19. METHODS: Retrospective, uncontrolled multicentre single-arm case series of hospitalised patients with laboratory-confirmed COVID-19, treated with inhaled nebulised UFH (5000 IU q8h, 10 000 IU q4h, or 25 000 IU q6h) for 6 ± 3 (mean ± standard deviation) days. Outcomes were activated partial thromboplastin time (APTT) before treatment (baseline) and highest-level during treatment (peak), and adverse events including bleeding. Exploratory efficacy outcomes were oxygenation, assessed by ratio of oxygen saturation to fraction of inspired oxygen (FiO2 ) and FiO2 , and the World Health Organisation modified ordinal clinical scale. RESULTS: There were 98 patients included. In patients on stable prophylactic or therapeutic systemic anticoagulant therapy but not receiving therapeutic UFH infusion, APTT levels increased from baseline of 34 ± 10 seconds to a peak of 38 ± 11 seconds (P < .0001). In 3 patients on therapeutic UFH infusion, APTT levels did not significantly increase from baseline of 72 ± 20 to a peak of 84 ± 28 seconds (P = .17). Two patients had serious adverse events: bleeding gastric ulcer requiring transfusion and thigh haematoma; both were on therapeutic anticoagulation. Minor bleeding occurred in 16 patients, 13 of whom were on therapeutic anticoagulation. The oxygen saturation/FiO2 ratio and the FiO2 worsened before and improved after commencement of inhaled UFH (change in slope, P < .001). CONCLUSION: Inhaled nebulised UFH in hospitalised patients with COVID-19 was safe. Although statistically significant, inhaled nebulised UFH did not produce a clinically relevant increase in APTT (peak values in the normal range). Urgent randomised evaluation of nebulised UFH in patients with COVID-19 is warranted and several studies are currently underway.
引用
- van Haren FMP, van Loon LM, Steins A, et al. Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. Br J Clin Pharmacol. 2022. PMID: 34984714. doi:10.1111/bcp.15212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。